AKRO stock icon

Akero Therapeutics
AKRO

$23.98
2.6%
 

About: Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Employees: 58

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 8 analysts
0
News positive %
of 83 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 4 (+2) [Q1 2024]

62% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 45

57% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 23

34% more capital invested

Capital invested by funds: $1.38B [Q4 2023] → $1.84B (+$467M) [Q1 2024]

8% more funds holding

Funds holding: 156 [Q4 2023] → 169 (+13) [Q1 2024]

0.03% more ownership

Funds ownership: 105.89% [Q4 2023] → 105.92% (+0.03%) [Q1 2024]

24% less call options, than puts

Call options by funds: $10.8M | Put options by funds: $14.2M

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$30
25%
upside
Avg. target
$45
87%
upside
High target
$56
134%
upside

8 analyst ratings

positive
88%
neutral
13%
negative
0%
HC Wainwright & Co.
Ed Arce
109%upside
$50
Buy
Reiterated
11 Jun 2024
Evercore ISI Group
Liisa Bayko
58%upside
$38
Outperform
Maintained
15 May 2024
Canaccord Genuity
Edward Nash
134%upside
$56
Buy
Maintained
13 May 2024
HC Wainwright & Co.
Ed Arce
109%upside
$50
Buy
Reiterated
13 May 2024
B of A Securities
Alexandria Hammond
25%upside
$30
Neutral
Reinstated
22 Apr 2024

Financial journalist opinion

Based on 83 articles about AKRO published over the past 30 days